BioNTech's CEO Just Sold His Last Direct Shares. Read the Footnote Before You Panic
Ugur Sahin sold all 214,209 BioNTech shares he held directly in 7 trading days under a plan set June 3, and still holds 39.2M through Medine GmbH.
The CEO of BioNTech just took his direct share count to zero
Ugur Sahin sold all 214,209 BioNTech shares he held in his own name between October 1 and October 9, 2026, roughly $20.6 million at an average near $96 a share. Sahin co-founded BioNTech, the German drugmaker that built its COVID-19 vaccine with Pfizer, and is its CEO. His final Form 4 shows 0 shares in the direct ownership column.
Read cold, that is a bad headline: “CEO sells every share.” NexusAlert flagged the filing as a High severity insider alert, and the press covered each tranche as its own small story.
Seven trading days, one schedule
The sales were not one block. They were seven consecutive trading days of open-market sales, which is what a pre-set schedule looks like.
| Trade date | Shares sold | Price per share | Approx. proceeds |
|---|---|---|---|
| Oct 1 | 17,000 | $97.46 | $1.66M |
| Oct 2 | 17,000 | $96.72 | $1.64M |
| Oct 5 | 72,000 | $97.23 | $7.00M |
| Oct 6 | 21,000 | $96.81 | $2.03M |
| Oct 7 | 24,000 | $95.86 | $2.30M |
| Oct 8 | 27,000 | $92.31 | $2.49M |
| Oct 9 | 36,209 | $95.37 | $3.45M |
| Total | 214,209 | about $96.08 average | about $20.6M |
The last Form 4, filed October 9, covers the October 8 and October 9 trades: 27,000 shares plus 36,209 shares, which is the 63,209 total in the headline numbers. After the final sale, the direct column reads zero.
So is it a red flag? Not on its own
Open the filing’s remarks and the story changes. Every one of these sales was made under a Rule 10b5-1 trading plan that Sahin set up on June 3, 2026, four months before the first trade. A 10b5-1 plan fixes the selling schedule in advance, so the dates and sizes were not chosen in reaction to anything that happened in October.
The second footnote matters even more. Sahin still owns 39,218,111 BioNTech shares through Medine GmbH, a holding company of which he is the sole shareholder. At the $96.96 price shown on the BNTX Company Dossier, that stake is worth about $3.8 billion. What he sold is roughly 0.5% of his total position.
That is the misconception worth busting. “Sold every share” describes one column on one form. It does not describe the stake.
There is a fair counterpoint. A plan sale is still a sale, and a CEO who is happy to sell about $20.6 million of stock at $96 is telling you something about his personal finances, if not his view of the business. The plan also leaves the future open: the October 9 Form 4 ends this run of direct sales, but it says nothing about what Medine GmbH might do next.
The bigger pattern: one Form 4 is never the story
The BNTX Company Dossier shows why the single alert undersells the situation. In one week it logged three separate High severity insider signals on Sahin, each one a fresh Form 4 that the press treated as an isolated item.
Zoom out and the Dossier’s Insider activity card shows insider net flow of negative $89.8 million across 27 Form 4 transactions, all from C-suite executives. The card also carries a Form 144 line: 7 notices worth $428.6 million this period, compared with $89.1 million over the trailing 90 days. A Form 144 is a notice of a proposed sale, not a completed one, and the Dossier does not break the total out by insider, so treat it as a measure of how much selling has been announced, not a forecast.
One more detail shows why the context matters. NexusAlert leaves BioNTech’s Insider Conviction score unrated, because the Dossier finds zero discretionary transactions over the past 12 months. Plan-driven sales carry less information about a CEO’s mood than a sale he chose to make on a random Tuesday.
What to check before you react to any insider sale
A zero in the direct column is not a zero in the stake.
Every insider filing hides the same three questions in its footnotes. When was the trading plan adopted? What does the insider hold indirectly, through trusts or holding companies? How big is the sale next to the whole position?
Answer those and “CEO dumps everything” becomes something you can actually size. Skip them and you are trading the headline.
That is the reason NexusAlert exists: it puts the filing, the history behind it and the Company Dossier in one place, the same day the Form 4 lands. Read the whole filing, not the headline.
Create a free NexusAlert account
Sources
- BioNTech SE Form 4, trades Oct 8 and Oct 9, 2026 (SEC EDGAR)
- BioNTech SE Form 4, trade Oct 7, 2026 (SEC EDGAR)
- BioNTech SE Form 4, trades Oct 5 and Oct 6, 2026 (SEC EDGAR)
- BioNTech SE Form 4, trades Oct 1 and Oct 2, 2026 (SEC EDGAR)
- Under a trading plan, BioNTech CEO Ugur Sahin sells 36,209 and 27,000 shares (StockTitan)
- BioNTech CEO sells all direct shares under trading plan (Defense World)
- BNTX Company Dossier (NexusAlert)
Prefer to own it outright? NexusAlert lifetime access is available for a one-time payment of $299 — no subscription, no recurring charges, all future Pro features included. Learn more →